Kevin Kalinsky, MD

Articles

Dr Kalinsky on Unanswered Questions Regarding Genomic Testing in HR+ Breast Cancer

March 8th 2024

Kevin Kalinsky, MD, MS, discusses questions regarding the utility and implementation of genomic testing approaches in hormone receptor–positive breast cancer.

Dr. Kalinsky on the Evolving Treatment Landscape and Sequencing ADCs in TNBC

March 3rd 2023

Kevin Kalinsky, MD, MS, discusses the evolving treatment landscape for patients with triple-negative breast cancer and how to best sequence antibody-drug conjugates within this population.

Dr. Kalinsky on Chemotherapy for Premenopausal Patients With HR+/HER2- Breast Cancer

October 13th 2022

Kevin Kalinsky, MD, MS, discusses the role of chemotherapy with ovarian function suppression and hormonal therapy for premenopausal patients with HR–positive/HER2-negative breast cancer.

Latest in Lung, Genitourinary, Gynecologic, and Breast Cancers From ASCO 2022: Drs Charu Aggarwal, Bradley McGregor, Robert Coleman, and Kevin Kalinsky

June 7th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Dr. Kalinsky on the Potential of ADCs Across Breast Cancer Subtypes

March 6th 2021

Kevin Kalinsky, MD, MS, discusses the potential of antibody-drug conjugates across breast cancer subtypes.

Dr. Kalinsky on Optical Imaging for HER2+ Breast Cancer

February 21st 2017

Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses the potential advantages of optical imaging for patients with HER2-positive breast cancer.

Dr. Kalinsky on Ruxolitinib Plus Trastuzumab in HER2-Positive Breast Cancer

January 11th 2017

Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses a phase I study of ruxolitinib (Jakafi) in combination with trastuzumab (Herceptin) in metastatic HER2-positive breast cancer.